Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores

BACKGROUND: Both tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are known to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to compare the difference in HCC risk reduction between TDF and ETV in treatment-naïve patients with CH...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yan, Chen, Lichang, Huang, Rui, Zhu, Chuanwu, Shang, Jia, Qian, Yunsong, Lian, Jianqi, Liu, Longgen, Jiang, Jianning, Liu, Chenghai, Gui, Honglian, Xie, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218453/
https://www.ncbi.nlm.nih.gov/pubmed/35757781
http://dx.doi.org/10.1177/20406223221102791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218453/
https://www.ncbi.nlm.nih.gov/pubmed/35757781
http://dx.doi.org/10.1177/20406223221102791

Ejemplares similares